Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst₃ Antagonist

This letter provides the first pharmacological proof of principle that the sst₃ receptor mediates glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells. To enable these studies, we identified the selective sst₃ antagonist (1<i>R</i>,3<i>R</i>)-3-(5-phenyl-1<i>H</i>-imidazol-2-yl)-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-2,3,4,9-tetrahydro-1<i>H</i>-β-carboline (<b>5a</b>), with improved ion channel selectivity and mouse pharmacokinetic properties as compared to previously described tetrahydro-β-carboline imidazole sst3 antagonists. We demonstrated that compound <b>5a</b> enhances GSIS in pancreatic β-cells and blocks glucose excursion induced by dextrose challenge in ipGTT and OGTT models in mice. Finally, we provided strong evidence that these effects are mechanism-based in an ipGTT study, showing reduction of glucose excursion in wild-type but not sst₃ knockout mice. Thus, we have shown that antagonism of sst₃ represents a new mechanism with potential in treating type 2 diabetes mellitus